SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Libeo 10 mg chewable tablets for dogs

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each tablet contains:

Active substance: Furosemide 10 mg

Excipients:

Qualitative composition of excipients and other constituents

Chicken flavour

Yeast extract (Saccharomices cerevisiae)

Maltodextrine

Magnesium stearate

Silica, colloidal anhydrous

Microcrystalline cellulose

Sodium croscarmellose

Lactose monohydrate

Chewable tablet

Clover shape beige tablet. The tablets can be divided into equal quarters.

3. CLINICAL INFORMATION

3.1 Target species

Dogs

3.2 Indications for use for each target species

Treatment of ascites and oedema, particularly associated with cardiac insufficiency.

3.3 Contraindications

Do not use in dogs suffering from hypovolaemia, hypotension or dehydration.

Do not use in cases of renal failure with anuria.

Do not use in cases of electrolyte deficiency.

Do not use in cases of hypersensitivity to furosemide, sulfonamides or to any of the excipients.

3.4 Special warnings

Therapeutic efficacy may be impaired by increased intake of drinking water. Where the animal’s condition permits, water intake should be restricted to physiologically normal levels during treatment.

3.5 Special precautions for use

Special precautions for safe use in the target species:

As the tablets are flavoured, they should be stored in a safe place out of the reach of animals.

Furosemide should be used with caution in case of pre-existing electrolyte and/or water imbalance, impaired hepatic function (may precipitate hepatic coma) and diabetes mellitus. In case of prolonged treatment, hydration status and serum electrolytes should be monitored frequently.

1-2 days before and after commencement of treatment with diuretics and ACE inhibitors renal function and hydration status should be monitored.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

People with known hypersensitivity to furosemide should avoid contact with the veterinary medicinal product. Wash hands after use.

Do not handle this product if you know you are sensitive to sulphonamides as hypersensitivity to sulphonamides may lead to hypersensitivity to furosemide. If you develop symptoms following exposure such as a skin rash, you should seek medical advice and show the doctor this warning. Swelling of the face, lips or eyes or difficulty with breathing are more serious symptoms and require urgent medical attention.

In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

Special precautions for the protection of the environment:

Not applicable.

3.6 Adverse events Dog:

Rare (1 to 10 animals / 10,000 animals treated):	Soft stool[1] Dehydration[2], Electrolyte disorder2 (e.g. hypokalaemia, hyponatremia)
Undetermined frequency (cannot be estimated from the available data)	Haemoconcentration[3] Poor peripheral circulation3

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

3.7 Use during pregnancy, lactation or lay

Pregnancy and lactation:

Laboratory studies have produced evidence of teratogenic effects.

The safety of the product has not been established in pregnant and lactating bitches however, furosemide is excreted into milk.

In pregnant and lactating animals, use only according to the benefit/risk assessment by the responsible veterinarian.

3.8 Interaction with other medicinal products and other forms of interaction

Concurrent use with drugs affecting electrolyte balance (corticosteroids, other diuretics, amphotericin B, cardiac glycosides) requires careful monitoring.

Concomitant use with aminoglycosides or cephalosporins may increase the risk of nephrotoxicity.

Furosemide may increase the risk of sulfonamide allergy.

Furosemide may alter insulin requirements in diabetic animals.

Furosemide may reduce the excretion of NSAIDs.

The dose regimen may need to be modified for long term treatment in combination with ACE inhibitors, depending upon the animal’s response to therapy. Cross reactivity to sulfonamides is possible.

3.9 Administration routes and dosage

Oral use.

1 to 5 mg furosemide/kg bodyweight per day, i.e ½ to 2.5 tablets per 5 kg bodyweight of the product, given in a single dose or in two divided daily doses. Depending on the severity of the oedema or ascites or in refractory cases, the daily dose may be doubled.

Example for a targeted dose of 1mg/kg per administration:

	Tablets per administration
	Libeo 10 mg
2 – 3.5 kg	1/4
3.6 – 5 kg	½
5.1-7.5 kg	3/4
7.6 – 10 kg	1
10.1-12.5 kg	1 1/4
12.6 – 15 kg	1 1/2

To ensure a correct dosage, body weight should be determined as accurately as possible.

For dogs of 15.1 to 50 kg bodyweight use Libeo 40 mg tablets.

For maintenance, the dosage should be adapted to the lowest effective dose by the veterinarian depending on the clinical response of the dog to the therapy.

The dosage and schedule may have to be adjusted depending on the condition of the animal.

If treatment is administered last thing at night this may result in inconvenient diuresis overnight.

Instruction on how to divide the tablet: Put the tablet on a plain surface, with its scored side facing the surface (convex face up). With the tip of forefinger, exert a slight vertical pressure on the middle of the tablet to break it in its width into halves. In order to obtain quarters, then exert a slight pressure on the middle of one half with forefinger to break it in its length.

The tablets are flavoured and may be mixed with a small amount of food offered prior to the main meal, or administered directly into the mouth.

3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

Doses higher than recommended may cause transitory deafness, electrolyte and water balance problems CNS effects (lethargy, coma, seizures) and cardiovascular collapse.

Treatment should be symptomatic.

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

Not applicable.

3.12 Withdrawal periods

Not applicable

4. PHARMACOLOGICAL INFORMATION

4.1 ATCvet code:

QC03CA01

4.2 Pharmacodynamics

Furosemide is a potent loop diuretic that increases urinary volume. It inhibits electrolyte resorption in the proximal and distal renal tubules and in the ascending Loop of Henle. Excretion of sodium ions, chloride ions and to a lesser extent, potassium ions is enhanced, as is water excretion. Furosemide has no effect on carbonic anhydrase.

4.3 Pharmacokinetics

Furosemide is excreted unchanged in the urine.

After oral administration of the product (5 mg/kg), furosemide is rapidly absorbed with maximum plasma levels (Cmax of 2126ng/mL) occurring within 1.1 hour. The terminal half life of elimination is 2.6 hours.

Furosemide is predominantly eliminated via the kidneys in the urine (70 %) and via the faeces. Plasma protein binding of furosemide is 91% and estimated distribution volume is 0.52 L/kg. Furosemide metabolizes in very small amounts (main metabolite: 4-chloro-5-sulfamoyl-anthranilic-acid, no diuretic activity).

In dogs, after oral administration, furosemide causes a dose-dependent increase in urine volume starting 1 hour after administration, reaching a maximum 2-3 hours post administration and lasting approximately 6 hours.

5. PHARMACEUTICAL PARTICULARS

5.1 Major incompatibilities

Not applicable

5.2 Shelf life

Shelf-life of the veterinary medicinal product as packaged for sale:

30 months

Any part-used tablet should be used within 72 hours.

5.3 Special precautions for storage

Do not store above 30°C.

Any part-used tablet should be returned to the opened blister

5.4 Nature and composition of immediate packaging

(white PVC –PVDC – aluminium heat sealed) containing 10 tablets per blister

Cardboard box of 10 tablets containing 1 blister of 10 tablets

Cardboard box of 20 tablets containing 2 blisters of 10 tablets

Cardboard box of 100 tablets containing 10 blisters of 10 tablets

Cardboard box of 120 tablets containing 12 blisters of 10 tablets Cardboard box of 200 tablets containing 20 blisters of 10 tablets Not all pack sizes may be marketed.

5.5 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Medicines should not be disposed of via wastewater.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

6. NAME OF THE MARKETING AUTHORISATION HOLDER

Ceva Sante Animale

7. MARKETING AUTHORISATION NUMBERS

Vm 14966/5041

Vm 14966/3040

8. DATE OF FIRST AUTHORISATION

04 March 2014

9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

October 2025

10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCT

Veterinary medicinal product subject to prescription.

Find more product information by searching for the ‘Product Information Database’ on www.gov.uk.

Gavin Hall Approved: 03 October 2025

---